Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria; NRC Institute of Immunology FMBA of Russia, Moscow, Russia.
Laboratory of Immunopathology, Department of Clinical Immunology and Allergy, Sechenov First Moscow State Medical University, Moscow, Russia.
Adv Immunol. 2018;138:195-256. doi: 10.1016/bs.ai.2018.03.002. Epub 2018 Apr 26.
Immunoglobulin E (IgE)-associated allergy is the most common immune disorder. More than 30% of the population suffer from symptoms of allergy which are often severe, disabling, and life threatening such as asthma and anaphylaxis. Population-based birth cohort studies show that up to 60% of the world population exhibit IgE sensitization to allergens, of which most are protein antigens. Thirty years ago the first allergen-encoding cDNAs have been isolated. In the meantime, the structures of most of the allergens relevant for disease in humans have been solved. Here we provide an update regarding what has been learned through the use of defined allergen molecules (i.e., molecular allergology) and about mechanisms of allergic disease in humans. We focus on new insights gained regarding the process of sensitization to allergens, allergen-specific secondary immune responses, and mechanisms underlying allergic inflammation and discuss open questions. We then show how molecular forms of diagnosis and specific immunotherapy are currently revolutionizing diagnosis and treatment of allergic patients and how allergen-specific approaches may be used for the preventive eradication of allergy.
免疫球蛋白 E(IgE)相关过敏是最常见的免疫失调。超过 30%的人群患有过敏症状,这些症状往往严重、致残且危及生命,例如哮喘和过敏反应。基于人群的出生队列研究表明,高达 60%的世界人口对过敏原表现出 IgE 致敏,其中大多数是蛋白质抗原。三十年前,人们首次分离出了编码过敏原的 cDNA。与此同时,与人类疾病相关的大多数过敏原的结构已经得到解决。在这里,我们将提供有关通过使用定义明确的过敏原分子(即分子过敏原学)所学到的知识,以及有关人类过敏疾病机制的最新信息。我们重点介绍了在过敏原致敏、过敏原特异性二次免疫反应以及过敏炎症的机制方面获得的新见解,并讨论了悬而未决的问题。然后,我们展示了分子形式的诊断和特异性免疫疗法如何正在彻底改变过敏患者的诊断和治疗,以及过敏原特异性方法如何用于预防过敏的消除。